CTOs on the Move

Uroplasty

www.uroplasty.com

 
Uroplasty is a global medical company committed to offering transformative treatment options through specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Uroplasty’s products include the Urgent® PC Neuromodulation System, a non-drug, non-surgical office-based treatment for Overactive Bladder and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Urgent PC is an FDA-cleared system that delivers PTNS (Percutaneous Tibial Nerve Stimulation) and is also indicated for the treatment of fecal incontinence outside the US market. Uroplasty also offers Macroplastique®, an injectable urethral bulking agent ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Accelerated Rehabilitation Centers

Accelerated Rehabilitation Centers is an independent, private rehabilitation practice. Physical Therapist owned with over 160 physical rehabilitation centers throughout the Midwest and Arizona.

A Helpmate

A Helpmate is a Rancho Cordova, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Word and Brown

Word and Brown is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Pure Power Athletics d/b/a Makkar Athletics Group

Pure Power Athletics, Inc. d/b/a Makkar Athletics Group is a Oakville, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immune Pharmaceuticals

Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.